Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus.

  title={Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus.},
  author={Gabriel Moeddel and Sabine Bunten and Christine Dobis and Stjepana Kovac and Mustafa Doğan and Marthe Fischera and Rainer Dziewas and Wolf R{\"u}diger Sch{\"a}bitz and Stefan Evers and Svenja Happe},
  journal={Journal of neurology, neurosurgery, and psychiatry},
  volume={80 6},
The purpose of this study was to investigate the safety and efficacy of intravenous levetiracetam (LEV-iv) in refractory status epilepticus (SE). A retrospective chart review was performed on patients who received LEV-iv for treatment of SE (n = 36) and had failed at least one other antiepileptic drug. LEV-iv (median 3000 mg/day; range 1000-9000) was administered as a bolus loading (500-2000 mg per 30-60 min, n = 30) or as a continuous pump infusion (n = 6). SE was terminated in 69… CONTINUE READING
30 Citations
22 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 30 extracted citations


Publications referenced by this paper.
Showing 1-10 of 22 references

Levetiracetam intravenous infusion : safety , tolerability and bioavailability versus oral tablet

  • S Ramael, A Daoust, C Otoul
  • Clin Ther
  • 2006

Case series : Treatment with levetiracetam in nonconvulsive status epilepticus

  • AO Rossetti, EB Bromfield
  • Epilepsia
  • 2005

Similar Papers

Loading similar papers…